Paul Manganelli, MD
Interventional Pain Medicine · Naperville, ILNPI 1841247236
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,611 of the $13,976 with a category attached, or 61.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 13.7%. Reporting peaked in 2019 at $5,404 and has fallen 65.6% since, to $1,858 in 2025.
Across 212 payments — averaging $65.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertiflex, Inc.$2K
- Abbott$2K
- Boston Scientific$2K
- Medtronic$1K
- Nevro Corp.$1K
- Saluda Medical Americas, Inc.$1K
- plus $5K from 22 others
What the payments were for
- Travel & lodging$4,98136%
- Food & beverage$8,61162%
- Education$3843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertiflex, Inc. | 9 | $1,913 |
| Abbott | 23 | $1,675 |
| Boston Scientific | 30 | $1,669 |
| Medtronic(2 entities) | 17 | $1,367 |
| Nevro Corp. | 41 | $1,334 |
| Saluda Medical Americas, Inc. | 6 | $1,271 |
| Globus Medical | 14 | $1,164 |
| Relievant Medsystems, Inc. | 7 | $911 |
| SPR Therapeutics, Inc | 9 | $529 |
| Nalu Medical, Inc. | 5 | $372 |
| Curonix LLC | 7 | $292 |
| MML US, Inc. | 2 | $235 |
| Averitas Pharma Inc. | 3 | $190 |
| Biotronik NRO, Inc. | 5 | $182 |
| Stimwave Technologies Incorporated | 8 | $127 |
| Spinal Simplicity, LLC | 6 | $123 |
| Medwest Associates | 1 | $117 |
| Tersera Therapeutics LLC | 4 | $108 |
| GRT US Holding, Inc. | 1 | $93 |
| Pfizer | 4 | $72 |
| Si-bone, Inc. | 2 | $66 |
| Orexo US, Inc. | 2 | $47 |
| Stryker | 1 | $31 |
| Johnson & Johnson | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Vertos Medical, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
| Arteriocyte Medical Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,226
- Superion ISS$1,771
- Evoke SCS$1,098
- OSTEOCOOL RF ABLATION$1,064
- Vyrsa V1$735
- SPECTRA WAVEWRITER$578
- Senza Spinal Cord Stimulation System$534
- SPRINT PNS System$409
- Proclaim IPG$318
- GENERAL PAIN MANAGEMENT$256
- Senza$248
- ReActiv8$169
- Evoke$143
- Nalu Neurostimulation System$121
- Qutenza$113
How this compares
$13,976 in reported general payments places this provider in the 85th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 266 | $33,294 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 611 | $13,663 |
| Buprenorphine | 25 | $11,048 |
| MovantikNaloxegol Oxalate | 13 | $7,678 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 256 | $6,309 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $5,166 |
| Xtampza ErOxycodone Myristate | 14 | $4,918 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 26 | $3,875 |
| Tramadol Hcl ErTramadol Hcl | 12 | $3,604 |
| Gabapentin | 243 | $2,330 |
| Tramadol Hcl | 260 | $1,698 |
| Naloxone Hcl | 21 | $1,670 |
| Fentanyl | 14 | $1,402 |
| Tizanidine Hcl | 93 | $1,287 |
| Pregabalin | 75 | $1,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $19 | $4,91814 claims |
| Orexo US, Inc.Zubsolv | $47 | $3,87526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 interventional pain medicine providers in Illinois.
Other interventional pain medicine in Naperville
- Yousuf SayeedNaperville$13K
- John GashkoffNaperville$12K
- Alexander FeoktistovNorthfield$922K
- Timothy LubenowChicago$556K
- Sandeep AminChicago$430K
- Matthew JaycoxChicago$123K
- Hong VoChicago$91K
- Asokumar BuvanendranChicago$52K
- Ramsin BenyaminBloomington$32K
- Adam YoungChicago$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.